Skip to content
★ Sign in to follow
DS

Dustin S. Sjuts

Executive
Chief Executive Officer
Revance Therapeutics, Inc.
Total declarations
38
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (4 ops.)
€1.5M

Latest filing published 19 Mar 2024 for Revance Therapeutics, Inc., €14k.

Filing timeline

BuySale
Dustin S. Sjuts

Insider track record

Disclosed buys
0
Disclosed sells
4

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Dustin S. Sjuts: trading record in brief

Dustin S. Sjuts (chief executive) discloses dealings in Revance Therapeutics, Inc. to SEC (Form 4). In total, 38 filings cover trades dated from 15 December 2019 to 18 March 2024.

No open-market purchase appears, only 4 sales worth €1.5M. Outside the open market, there are 30 share grants. Since January 2024: no purchases and 1 sale on the market.

Most recently, on 19 March 2024, the filings show an open-market sale worth €43k in Revance Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Companies and markets linked to Dustin S. Sjuts

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations19 total

19 of 19 declarations